)
Visual
test
Immunovia
Immunovia (IMMNOV) investor relations material
Immunovia Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary24 Feb, 2026
Executive summary
Achieved commercial launch of PancreaSure in September 2025 after over two years of development and clinical research, with strong adoption in high-risk surveillance centers and positive reception from the medical community.
Published five clinical studies, including pivotal CLARITI and VERIFI validation studies, and received recognition at major scientific conferences.
Built strong advocacy among key opinion leaders and high-risk surveillance centers, with early adoption by 12 centers by year-end 2025.
Secured $897 Medicare reimbursement rate and raised over 140 million SEK to support launch and clinical studies.
Added three strategic account managers to accelerate adoption and integration at key centers.
Financial highlights
Q4 2025 net sales were SEK 354,000, mainly from royalty and PancreaSure test revenues, down from SEK 455,000 in Q4 2024.
Operating loss for Q4 2025 was SEK 16.4 million, improved from SEK 30.1 million in Q4 2024.
Cash burn in Q4 was SEK 6.6 million per month, below guidance, with a year-end cash position of SEK 77.5 million.
Rights issue in Q4 2025 raised 100 million SEK (net SEK 69.8 million), extending cash runway through Q3 2026.
Cash flow from operating activities improved to -19.8 MSEK in Q4 2025 from -28.3 MSEK in Q4 2024.
Outlook and guidance
Expect meaningful revenue from PancreaSure after 2026, with significant ramp-up in 2027.
Cash runway secured through Q3 2026 based on current cash balance and cost management.
Plan to submit for Medicare coverage in mid-2026, with some Medicare Advantage reimbursement expected in 2026.
Initial clinical utility data anticipated in Q2 2026.
Additional capital will be needed to fund operations beyond Q3 2026; exploring grants, partnerships, and equity options.
PancreaSure adoption rate and volume trends
Path to Medicare coverage post-Q2 utility data
Strategic partner impact on post-Q3 2026 funding
How will new sales staff accelerate pipeline?
How will clinical utility data secure Medicare coverage?
What is the plan to fund operations beyond Q3 2026?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Immunovia
- Next-gen test achieves 98% specificity, 85% sensitivity; rights issue funds 2025 US launch.IMMNOV
Q2 20242 Feb 2026 - Next-gen test nears US launch as costs fall and funding secured for clinical validation.IMMNOVQ3 202412 Jan 2026
- A new blood test detects early pancreatic cancer with 78% sensitivity and 94% specificity.IMMNOVStudy Update11 Jan 2026
- Test detected 77% of early-stage pancreatic cancers with 88% specificity in high-risk groups.IMMNOVStudy Update26 Dec 2025
- Next-gen test validated with 78% sensitivity, 94% specificity; US launch and strong liquidity for 2025.IMMNOVQ4 202423 Dec 2025
- PancreaSure's launch drives early adoption, clinical validation, and secures funding for growth.IMMNOVQ3 202515 Dec 2025
- September 2025 launch set, with strong data, doubled market, and cash runway through Q3 2025.IMMNOVQ1 202526 Nov 2025
- New blood test for early pancreatic cancer launches, with Q2 cost cuts and SEK 100M rights issue.IMMNOVQ2 202523 Nov 2025
Next Immunovia earnings date
Q1 20267 May, 2026
Immunovia
Next Immunovia earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage